

# Roberto Ceravolo

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7857249/publications.pdf>

Version: 2024-02-01

243  
papers

9,209  
citations

53939

47  
h-index

66518

82  
g-index

250  
all docs

250  
docs citations

250  
times ranked

10657  
citing authors

#	ARTICLE	IF	CITATIONS
1	Adult-onset mitochondrial movement disorders: a national picture from the Italian Network. <i>Journal of Neurology</i> , 2022, 269, 1413-1421.	1.8	10
2	Bipolar Spectrum disorders in Parkinsonâ€™s disease: a systematic evaluation. <i>CNS Spectrums</i> , 2022, 27, 355-361.	0.7	6
3	Pragmatic Approach on Neuroimaging Techniques for the Differential Diagnosis of Parkinsonisms. <i>Movement Disorders Clinical Practice</i> , 2022, 9, 6-19.	0.8	21
4	Early Compensatory Mechanisms in <sc>LRRK2</sc> Mutation Carriers. <i>Movement Disorders</i> , 2022, 37, 662-663.	2.2	0
5	Do neuropsychiatric fluctuations temporally match motor fluctuations in Parkinsonâ€™s disease?. <i>Neurological Sciences</i> , 2022, 43, 3641-3647.	0.9	3
6	Negative <sc>DATâ€SPECT</sc> in Old Onset Parkinson's Disease: An Additional Pitfall?. <i>Movement Disorders Clinical Practice</i> , 2022, 9, 530-534.	0.8	1
7	Fluid Biomarkers in Alzheimerâ€™s Disease and Other Neurodegenerative Disorders: Toward Integrative Diagnostic Frameworks and Tailored Treatments. <i>Diagnostics</i> , 2022, 12, 796.	1.3	4
8	Dysphagia in Parkinson's disease: Pharyngeal manometry and fiberoptic endoscopic evaluation. <i>Auris Nasus Larynx</i> , 2022, 49, 986-994.	0.5	4
9	Development and Validation of Automated <sc>Magnetic Resonance</sc> Parkinsonism Index 2.0 to Distinguish <sc>Progressive Supranuclear Palsyâ€Parkinsonism</sc> From <sc>Parkinson's Disease</sc>. <i>Movement Disorders</i> , 2022, 37, 1272-1281.	2.2	17
10	Î±-synuclein as an emerging pathophysiological biomarker of Alzheimerâ€™s disease. <i>Expert Review of Molecular Diagnostics</i> , 2022, 22, 411-425.	1.5	4
11	Increase in Mitochondrial D-Loop Region Methylation Levels in Mild Cognitive Impairment Individuals. <i>International Journal of Molecular Sciences</i> , 2022, 23, 5393.	1.8	9
12	Morphometric imaging and quantitative susceptibility mapping as complementary tools in the diagnosis of parkinsonisms. <i>European Journal of Neurology</i> , 2022, 29, 2944-2955.	1.7	4
13	Evaluation of iron overload in nigrosome 1 via quantitative susceptibility mapping as a progression biomarker in prodromal stages of synucleinopathies. <i>NeuroImage</i> , 2022, 260, 119454.	2.1	8
14	A New MRI Measure to Early Differentiate Progressive Supranuclear Palsy From De Novo Parkinson's Disease in Clinical Practice: An International Study. <i>Movement Disorders</i> , 2021, 36, 681-689.	2.2	22
15	Striatal Dopamine Deficit and Motor Impairment in Idiopathic Normal Pressure Hydrocephalus. <i>Movement Disorders</i> , 2021, 36, 124-132.	2.2	22
16	Exploring the clinical association between neurological symptoms and COVID-19 pandemic outbreak: a systematic review of current literature. <i>Journal of Neurology</i> , 2021, 268, 1561-1569.	1.8	39
17	Is DAT imaging abnormality in normal pressure hydrocephalus always suggestive of degeneration?. <i>Neurological Sciences</i> , 2021, 42, 723-726.	0.9	5
18	Functional motor disorders associated with other neurological diseases: Beyond the boundaries of â€œorganicâ€•neurology. <i>European Journal of Neurology</i> , 2021, 28, 1752-1758.	1.7	45

#	ARTICLE	IF	CITATIONS
19	Prevalence and impact of COVID-19 in Parkinson's disease: evidence from a multi-center survey in Tuscany region. <i>Journal of Neurology</i> , 2021, 268, 1179-1187.	1.8	70
20	Connected speech in progressive supranuclear palsy: a possible role in differential diagnosis. <i>Neurological Sciences</i> , 2021, 42, 1483-1490.	0.9	3
21	The PRIAMO study: age- and sex-related relationship between prodromal constipation and disease phenotype in early Parkinson's disease. <i>Journal of Neurology</i> , 2021, 268, 448-454.	1.8	16
22	Progress regarding the context-of-use of tau as biomarker of Alzheimer's disease and other neurodegenerative diseases. <i>Expert Review of Proteomics</i> , 2021, 18, 27-48.	1.3	8
23	Mild Cognitive Impairment in de novo Parkinson's Disease: Selective Attention Deficit as Early Sign of Neurocognitive Decay. <i>Frontiers in Psychology</i> , 2021, 12, 546476.	1.1	2
24	Î±-Synuclein Heteromers in Red Blood Cells of Alzheimer's Disease and Lewy Body Dementia Patients. <i>Journal of Alzheimer's Disease</i> , 2021, 80, 885-893.	1.2	9
25	Understanding the Multiple Role of Mitochondria in Parkinson's Disease and Related Disorders: Lesson From Genetics and Protein-Protein Interaction Network. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 636506.	1.8	44
26	Clinical Outcome and Striatal Dopaminergic Function After Shunt Surgery in Patients With Idiopathic Normal Pressure Hydrocephalus. <i>Neurology</i> , 2021, 96, e2861-e2873.	1.5	18
27	Prevalence and Clinical Correlates of Comorbid Anxiety and Panic Disorders in Patients with Parkinson's Disease. <i>Journal of Clinical Medicine</i> , 2021, 10, 2302.	1.0	8
28	Functional motor phenotypes: to lump or to split?. <i>Journal of Neurology</i> , 2021, 268, 4737-4743.	1.8	25
29	Mitochondrial D-Loop Region Methylation and Copy Number in Peripheral Blood DNA of Parkinson's Disease Patients. <i>Genes</i> , 2021, 12, 720.	1.0	14
30	P2X7 receptor/NLRP3 inflammasome complex and Î±-synuclein in peripheral blood mononuclear cells: a prospective study in newly diagnosed, untreated Parkinson's disease. <i>European Journal of Neurology</i> , 2021, 28, 2648-2656.	1.7	12
31	Spread of segmental/multifocal idiopathic adult-onset dystonia to a third body site. <i>Parkinsonism and Related Disorders</i> , 2021, 87, 70-74.	1.1	8
32	Statins in Parkinson's Disease: Influence on Motor Progression. <i>Journal of Parkinson's Disease</i> , 2021, 11, 1651-1662.	1.5	8
33	Ultrasensitive techniques and protein misfolding amplification assays for biomarker-guided reconceptualization of Alzheimer's disease and other neurodegenerative diseases. <i>Expert Review of Neurotherapeutics</i> , 2021, 21, 949-967.	1.4	4
34	Positive DAT-SCAN in SPG7: a case report mimicking possible MSA-C. <i>BMC Neurology</i> , 2021, 21, 328.	0.8	5
35	Orthostatic Hypotension in Parkinson's Disease: Do Height and Weight Matter?. <i>Movement Disorders</i> , 2021, 36, 2703-2705.	2.2	1
36	Sudden Onset, Fixed Dystonia and Acute Peripheral Trauma as Diagnostic Clues for Functional Dystonia. <i>Movement Disorders Clinical Practice</i> , 2021, 8, 1107-1111.	0.8	5

#	ARTICLE	IF	CITATIONS
37	Dissecting the Interplay Between Time of Dementia and Cognitive Profiles in Lewy Body Dementias. <i>Journal of Alzheimer's Disease</i> , 2021, 84, 757-766.	1.2	1
38	Reply to: "Experience with a New Index to Differentiate Parkinson's Disease and Progressive Supranuclear Palsy" <i>Movement Disorders</i> , 2021, 36, 2208-2209.	2.2	0
39	Functional gait disorders: Demographic and clinical correlations. <i>Parkinsonism and Related Disorders</i> , 2021, 91, 32-36.	1.1	4
40	Dopamine Transporter Imaging, Current Status of a Potential Biomarker: A Comprehensive Review. <i>International Journal of Molecular Sciences</i> , 2021, 22, 11234.	1.8	19
41	The Molecular Neuroimaging of Tremor. <i>Current Neurology and Neuroscience Reports</i> , 2021, 21, 74.	2.0	2
42	Transcranial Direct Current Stimulation (tDCS) as a Useful Rehabilitation Strategy to Improve Cognition in Patients With Alzheimer's Disease and Parkinson's Disease: An Updated Systematic Review of Randomized Controlled Trials. <i>Frontiers in Neurology</i> , 2021, 12, 798191.	1.1	13
43	Midbrain MRI assessments in progressive supranuclear palsy subtypes. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2020, 91, 98-103.	0.9	39
44	Extended release levodopa at bedtime as a treatment for nocturia in Parkinson's disease: An open label study. <i>Journal of the Neurological Sciences</i> , 2020, 410, 116625.	0.3	13
45	Confabulations in Cases of Dementia: Atypical Early Sign of Alzheimer's Disease or Misleading Feature in Dementia Diagnosis?. <i>Frontiers in Psychology</i> , 2020, 11, 553886.	1.1	2
46	Cerebello-thalamo-cortical network is intrinsically altered in essential tremor: evidence from a resting state functional MRI study. <i>Scientific Reports</i> , 2020, 10, 16661.	1.6	50
47	The role of synaptic biomarkers in the spectrum of neurodegenerative diseases. <i>Expert Review of Proteomics</i> , 2020, 17, 543-559.	1.3	16
48	Idiopathic "Non-task-specific" Upper Limb Dystonia, a Neglected Form of Dystonia. <i>Movement Disorders</i> , 2020, 35, 2038-2045.	2.2	21
49	Fluid Candidate Biomarkers for Alzheimer's Disease: A Precision Medicine Approach. <i>Journal of Personalized Medicine</i> , 2020, 10, 221.	1.1	20
50	Different Clinical Contexts of Use of Blood Neurofilament Light Chain Protein in the Spectrum of Neurodegenerative Diseases. <i>Molecular Neurobiology</i> , 2020, 57, 4667-4691.	1.9	33
51	Impact of "Coronavirus Disease 2019" Pandemic on Cognition in Parkinson's Disease. <i>Movement Disorders</i> , 2020, 35, 1717-1718.	2.2	30
52	Clinical Correlates of Functional Motor Disorders: An Italian Multicenter Study. <i>Movement Disorders Clinical Practice</i> , 2020, 7, 920-929.	0.8	45
53	Association of transient orthostatic hypotension with falls and syncope in patients with Parkinson disease. <i>Neurology</i> , 2020, 95, e2854-e2865.	1.5	25
54	Demographic and clinical determinants of neck pain in idiopathic cervical dystonia. <i>Journal of Neural Transmission</i> , 2020, 127, 1435-1439.	1.4	22

#	ARTICLE	IF	CITATIONS
55	Motor and Sensory Features of Cervical Dystonia Subtypes: Data From the Italian Dystonia Registry. <i>Frontiers in Neurology</i> , 2020, 11, 906.	1.1	6
56	Red blood cell $\alpha$ -synuclein heteroaggregates can discriminate healthy controls from cognitively impaired subjects of the AD $\rightarrow$ LBD spectrum. <i>Alzheimer's and Dementia</i> , 2020, 16, e040618.	0.4	0
57	Sex differences in red blood cell $\alpha$ -synuclein protein and its heteroaggregates with amyloid $\beta$ and tau in early Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2020, 16, e042079.	0.4	0
58	Assessment of the integrity of the noradrenergic nucleus locus coeruleus during normal ageing by neuromelanin $\rightarrow$ T MRI. <i>Alzheimer's and Dementia</i> , 2020, 16, e043332.	0.4	0
59	In vivo assessment of the noradrenergic nucleus locus coeruleus in Alzheimer's disease and other types of dementia. <i>Alzheimer's and Dementia</i> , 2020, 16, e043616.	0.4	0
60	Reduced oligodendrocyte exosome secretion in multiple system atrophy involves SNARE dysfunction. <i>Brain</i> , 2020, 143, 1780-1797.	3.7	66
61	Lumboperitoneal shunt in idiopathic normal pressure hydrocephalus: a prospective controlled study. <i>Journal of Neurology</i> , 2020, 267, 2556-2566.	1.8	13
62	Benign versus malignant Parkinson disease: the unexpected silver lining of motor complications. <i>Journal of Neurology</i> , 2020, 267, 2949-2960.	1.8	26
63	Dopamine Transporter, Age, and Motor Complications in Parkinson's Disease: A Clinical and Single-Photon Emission Computed Tomography Study. <i>Movement Disorders</i> , 2020, 35, 1028-1036.	2.2	17
64	Early autonomic and cognitive dysfunction in PD, DLB and MSA: blurring the boundaries between $\alpha$ -synucleinopathies. <i>Journal of Neurology</i> , 2020, 267, 3444-3456.	1.8	17
65	The path to biomarker-based diagnostic criteria for the spectrum of neurodegenerative diseases. <i>Expert Review of Molecular Diagnostics</i> , 2020, 20, 421-441.	1.5	42
66	Automated MRI Classification in Progressive Supranuclear Palsy: A Large International Cohort Study. <i>Movement Disorders</i> , 2020, 35, 976-983.	2.2	38
67	Does acute peripheral trauma contribute to idiopathic adult-onset dystonia?. <i>Parkinsonism and Related Disorders</i> , 2020, 71, 40-43.	1.1	18
68	Theory of mind in Parkinson's disease: evidences in drug-naïve patients and longitudinal effects of dopaminergic therapy. <i>Neurological Sciences</i> , 2020, 41, 2761-2766.	0.9	4
69	Does the Degree of Trunk Bending Predict Patient Disability, Motor Impairment, Falls, and Back Pain in Parkinson's Disease?. <i>Frontiers in Neurology</i> , 2020, 11, 207.	1.1	15
70	Tardive Syndrome Associated With Tetrabenazine in Huntington Disease. <i>Journal of Clinical Psychopharmacology</i> , 2020, 40, 628-630.	0.7	2
71	Non-pharmacological interventions for Parkinson's disease mild cognitive impairment: future directions for research. <i>Neural Regeneration Research</i> , 2020, 15, 1650.	1.6	11
72	Cognitive disorders in normal pressure hydrocephalus with initial parkinsonism in comparison with de novo Parkinson's disease. <i>European Journal of Neurology</i> , 2019, 26, 74-79.	1.7	14

#	ARTICLE	IF	CITATIONS
73	Pisa syndrome in Idiopathic Normal Pressure Hydrocephalus. <i>Parkinsonism and Related Disorders</i> , 2019, 66, 40-44.	1.1	9
74	Postural Abnormalities in Parkinson's Disease: An Epidemiological and Clinical Multicenter Study. <i>Movement Disorders Clinical Practice</i> , 2019, 6, 576-585.	0.8	36
75	Validation of the Italian version of the PSP Quality of Life questionnaire. <i>Neurological Sciences</i> , 2019, 40, 2587-2594.	0.9	5
76	Molecular Imaging of the Dopamine Transporter. <i>Cells</i> , 2019, 8, 872.	1.8	62
77	Quantitative susceptibility mapping in atypical Parkinsonisms. <i>NeuroImage: Clinical</i> , 2019, 24, 101999.	1.4	49
78	Validation of the Italian version of carersâ€™ quality-of-life questionnaire for parkinsonism (PQoL). <i>Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50</i>	0.9	8
79	Clinical Correlates of Cerebral Amyloid Deposition in Parkinsonâ€™s Disease Dementia: Evidence from a PET Study. <i>Journal of Alzheimer's Disease</i> , 2019, 70, 597-609.	1.2	13
80	Orthostatic hypotension and REM sleep behaviour disorder: impact on clinical outcomes in Î±-synucleinopathies. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2019, 90, 1257-1263.	0.9	73
81	OC.05.3 HISTOMORPHOLOGICAL AND MOLECULAR CHARACTERIZATION OF PARKINSON'S DISEASE PATIENTS WITH CONSTIPATION: A PILOT STUDY. <i>Digestive and Liver Disease</i> , 2019, 51, e89.	0.4	0
82	Freezing of gait and dementia in parkinsonism: A retrospective caseâ€™control study. <i>Brain and Behavior</i> , 2019, 9, e01247.	1.0	8
83	Botulinum toxin for the treatment of dystonia and pain in corticobasal syndrome. <i>Brain and Behavior</i> , 2019, 9, e01182.	1.0	5
84	Potential Diagnostic Value of Red Blood Cells Î±-Synuclein Heteroaggregates in Alzheimerâ€™s Disease. <i>Molecular Neurobiology</i> , 2019, 56, 6451-6459.	1.9	24
85	Neuroimaging biomarkers for clinical trials in atypical parkinsonian disorders: Proposal for a Neuroimaging Biomarker Utility System. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2019, 11, 301-309.	1.2	30
86	Validity of the wall goniometer as a screening tool to detect postural abnormalities in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2019, 69, 159-165.	1.1	20
87	Progression of tremor in early stages of Parkinsonâ€™s disease: a clinical and neuroimaging study. <i>Brain</i> , 2018, 141, 811-821.	3.7	107
88	Present and Future of Ultra-High Field MRI in Neurodegenerative Disorders. <i>Current Neurology and Neuroscience Reports</i> , 2018, 18, 31.	2.0	10
89	Effect of type D personality on smoking status and their combined impact on outcome after acute myocardial infarction. <i>Clinical Cardiology</i> , 2018, 41, 321-325.	0.7	21
90	Head tremor as a warning symptom of rapidly progressive syringomyelia: a case report. <i>Neurological Sciences</i> , 2018, 39, 1497-1499.	0.9	0

#	ARTICLE	IF	CITATIONS
91	Aerobic rehabilitation program for improving muscle function in Parkinson's disease. Restorative Neurology and Neuroscience, 2018, 36, 13-20.	0.4	5
92	Oxidative Stress Assessment in Alzheimer's Disease: A Clinic Setting Study. American Journal of Alzheimer's Disease and Other Dementias, 2018, 33, 35-41.	0.9	15
93	The Precuneus – A Witness for Excessive A $\beta$ 2 Gathering in Alzheimer's Disease Pathology. Neurodegenerative Diseases, 2018, 18, 302-309.	0.8	13
94	Arterial stiffness and mitral regurgitation in arterial hypertension: an intriguing pathophysiological link. Vascular Pharmacology, 2018, 111, 71-76.	1.0	4
95	Advances in the pharmacotherapeutic management of dementia with Lewy bodies. Expert Opinion on Pharmacotherapy, 2018, 19, 1643-1653.	0.9	9
96	Social Cognition and Oxytocin in Huntington's Disease: New Insights. Brain Sciences, 2018, 8, 161.	1.1	11
97	$\beta$ -Synuclein Heterocomplexes with $\beta$ -Amyloid Are Increased in Red Blood Cells of Parkinson's Disease Patients and Correlate with Disease Severity. Frontiers in Molecular Neuroscience, 2018, 11, 53.	1.4	51
98	Blood-Based Biomarker Screening with Agnostic Biological Definitions for an Accurate Diagnosis Within the Dimensional Spectrum of Neurodegenerative Diseases. Methods in Molecular Biology, 2018, 1750, 139-155.	0.4	12
99	Brain-Derived Neurotrophic Factor (BDNF) and Serotonin Transporter (SERT) in Platelets of Patients with Mild Huntington's Disease: Relationships with Social Cognition Symptoms. Archives Italiennes De Biologie, 2018, 156, 27-39.	0.1	15
100	Molecular imaging to track Parkinson's disease and atypical parkinsonisms: New imaging frontiers. Movement Disorders, 2017, 32, 181-192.	2.2	88
101	Which patients discontinue? Issues on Levodopa/carbidopa intestinal gel treatment: Italian multicentre survey of 905 patients with long-term follow-up. Parkinsonism and Related Disorders, 2017, 38, 90-92.	1.1	44
102	Randomized trial on the effects of a combined physical/cognitive training in aged MCI subjects: the Train the Brain study. Scientific Reports, 2017, 7, 39471.	1.6	108
103	The Italian Dystonia Registry: rationale, design and preliminary findings. Neurological Sciences, 2017, 38, 819-825.	0.9	35
104	Gait dynamics in Pisa syndrome and Camptocormia: The role of stride length and hip kinematics. Gait and Posture, 2017, 57, 130-135.	0.6	22
105	Efficacy of a combined therapeutic approach in the management of Pisa Syndrome. NeuroRehabilitation, 2017, 41, 249-253.	0.5	6
106	Neuroimaging in Parkinson's disease: focus on substantia nigra and nigro-striatal projection. Current Opinion in Neurology, 2017, 30, 416-426.	1.8	19
107	A single center study: A $\beta$ 42/p-Tau181 CSF ratio to discriminate AD from FTD in clinical setting. Neurological Sciences, 2017, 38, 1791-1797.	0.9	16
108	Seven tesla MRI of the substantia nigra in patients with rapid eye movement sleep behavior disorder. Parkinsonism and Related Disorders, 2017, 43, 105-109.	1.1	23

#	ARTICLE	IF	CITATIONS
109	Striatal Dopamine Transporter Modulation After Rotigotine: Results From a Pilot Single-Photon Emission Computed Tomography Study in a Group of Early Stage Parkinson Disease Patients. <i>Clinical Neuropharmacology</i> , 2017, 40, 34-36.	0.2	10
110	Antipsychotic drugs in Huntingtonâ€™s disease. <i>Expert Review of Neurotherapeutics</i> , 2017, 17, 227-237.	1.4	27
111	Factors influencing psychological well-being in patients with Parkinsonâ€™s disease. <i>PLoS ONE</i> , 2017, 12, e0189682.	1.1	32
112	Levodopa and neuropathy risk in patients with Parkinson disease: Effect of COMT inhibition. <i>Parkinsonism and Related Disorders</i> , 2016, 27, 81-84.	1.1	24
113	Leadless cardiac pacemaker implant in a patient with two deep brain stimulators: A peaceful cohabitation beyond prejudices. <i>International Journal of Cardiology</i> , 2016, 223, 136-138.	0.8	4
114	Pathological Gambling in Parkinson's disease patients: Dopaminergic medication or personality traits fault?. <i>Journal of the Neurological Sciences</i> , 2016, 366, 167-170.	0.3	12
115	A review of adverse events linked to dopamine agonists in the treatment of Parkinsonâ€™s disease. <i>Expert Opinion on Drug Safety</i> , 2016, 15, 181-198.	1.0	30
116	Nigral involvement in atypical parkinsonisms: evidence from a pilot study with ultra-high field MRI. <i>Journal of Neural Transmission</i> , 2016, 123, 509-513.	1.4	16
117	Nigral anatomy and striatal denervation in genetic Parkinsonism: A family report. <i>Movement Disorders</i> , 2015, 30, 1148-1149.	2.2	18
118	Evaluating the SERCA2 and VEGF mRNAs as Potential Molecular Biomarkers of the Onset and Progression in Huntingtonâ€™s Disease. <i>PLoS ONE</i> , 2015, 10, e0125259.	1.1	18
119	Cataract Surgery under Topical Anesthesia in a Patient with Parkinson Disease and Deep Brain Stimulation: A Report of Feasibility. <i>European Journal of Ophthalmology</i> , 2015, 25, 258-259.	0.7	0
120	Doctor â€“ how quickly will my Parkinson's progress?. <i>European Journal of Neurology</i> , 2015, 22, 421-422.	1.7	2
121	Clinical variables associated with treatment changes in Parkinsonâ€™s disease: results from the longitudinal phase of the REASON study. <i>Neurological Sciences</i> , 2015, 36, 935-943.	0.9	6
122	Morphometric and functional MRI changes in essential tremor with and without resting tremor. <i>Journal of Neurology</i> , 2015, 262, 719-728.	1.8	39
123	Apomorphine hydrochloride for the treatment of Parkinsonâ€™s disease. <i>Expert Review of Neurotherapeutics</i> , 2015, 15, 723-732.	1.4	21
124	Reliability of administrative data for the identification of Parkinsonâ€™s disease cohorts. <i>Neurological Sciences</i> , 2015, 36, 783-786.	0.9	23
125	Mesolimbic dopaminergic dysfunction in Parkinsonâ€™s disease depression: evidence from a 123I-FP-CIT SPECT investigation. <i>Journal of Neural Transmission</i> , 2015, 122, 1143-1147.	1.4	23
126	A multidisciplinary consensus document on follow-up strategies for patients treated with percutaneous coronary intervention. <i>Catheterization and Cardiovascular Interventions</i> , 2015, 85, E129-39.	0.7	6



#	ARTICLE	IF	CITATIONS
127	Comparison of 3T and 7T Susceptibility-Weighted Angiography of the Substantia Nigra in Diagnosing Parkinson Disease. <i>American Journal of Neuroradiology</i> , 2015, 36, 461-466.	1.2	80
128	Pisa syndrome in Parkinson disease. <i>Neurology</i> , 2015, 85, 1769-1779.	1.5	72
129	Imaging in Glucocerebrosidase-Associated Parkinsonism: Current Status and Implications for Pathophysiology. <i>Neurodegenerative Diseases</i> , 2015, 15, 271-280.	0.8	3
130	Serotonergic antidepressant drugs and L-dopa-induced dyskinesias in Parkinson's disease. <i>Acta Neurologica Scandinavica</i> , 2015, 131, 191-195.	1.0	26
131	Current treatment and future prospects of dopa-induced dyskinesias. <i>Drugs of Today</i> , 2015, 51, 315.	0.7	14
132	MR Imaging of the Substantia Nigra for the Diagnosis of Parkinson Disease. <i>Radiology</i> , 2014, 273, 627-628.	3.6	1
133	Dopamine Agonist Modifies Cortical Activity in Parkinson Disease. <i>Clinical Neuropharmacology</i> , 2014, 37, 166-172.	0.2	1
134	Symptomatic orthostatic tremor associated with Gravesâ€™ disease. <i>Neurological Sciences</i> , 2014, 35, 929-931.	0.9	10
135	A pilot psychometric study of aberrant salience state in patients with Parkinsonâ€™s disease and its association with dopamine replacement therapy. <i>Neurological Sciences</i> , 2014, 35, 1603-1605.	0.9	4
136	MR Imaging of the Substantia Nigra at 7 T Enables Diagnosis of Parkinson Disease. <i>Radiology</i> , 2014, 271, 831-838.	3.6	114
137	Prevalence of fatigue in Parkinson disease and its clinical correlates. <i>Neurology</i> , 2014, 83, 215-220.	1.5	98
138	Imaging of the dopamine transporter predicts pattern of disease progression and response to levodopa in patients with schizophrenia and parkinsonism: A 2-year follow-up multicenter study. <i>Schizophrenia Research</i> , 2014, 152, 344-349.	1.1	38
139	Diabetes is associated with postural and cognitive domains in Parkinson's disease. Results from a single-center study. <i>Parkinsonism and Related Disorders</i> , 2014, 20, 671-672.	1.1	31
140	Caudate dopaminergic denervation and visual hallucinations: Evidence from a 123I-FP-CIT SPECT study. <i>Parkinsonism and Related Disorders</i> , 2014, 20, 761-765.	1.1	30
141	Adherence to anti-Parkinson drug therapy in the â€œREASONâ€ sample of Italian patients with Parkinsonâ€™s disease: the linguistic validation of the Italian version of the â€œMorisky Medical Adherence scale-8 itemsâ€. <i>Neurological Sciences</i> , 2013, 34, 2015-2022.	0.9	29
142	Diagnosis, assessment and management of delusional jealousy in Parkinsonâ€™s disease with and without dementia. <i>Neurological Sciences</i> , 2013, 34, 1537-1541.	0.9	14
143	Twinkle mutation in an Italian family with external progressive ophthalmoplegia and parkinsonism: A case report and an update on the state of art. <i>Neuroscience Letters</i> , 2013, 556, 1-4.	1.0	34
144	Reasons driving treatment modification in Parkinson's disease: Results from the cross-sectional phase of the REASON study. <i>Parkinsonism and Related Disorders</i> , 2013, 19, 1130-1135.	1.1	16

#	ARTICLE	IF	CITATIONS
145	Neuropathy and levodopa in Parkinson's disease: Evidence from a multicenter study. <i>Movement Disorders</i> , 2013, 28, 1391-1397.	2.2	114
146	The relationship between motor symptom lateralization and cognitive performance in newly diagnosed drug-naïve patients with Parkinson's disease. <i>Journal of Clinical and Experimental Neuropsychology</i> , 2013, 35, 124-131.	0.8	26
147	Nigral involvement and nigrostriatal dysfunction in Huntington's disease: Evidences from an MRI and SPECT study. <i>Parkinsonism and Related Disorders</i> , 2013, 19, 800-805.	1.1	13
148	Evidence of delayed nigrostriatal dysfunction in corticobasal syndrome: A SPECT follow-up study. <i>Parkinsonism and Related Disorders</i> , 2013, 19, 557-559.	1.1	33
149	A Single-Center, Cross-Sectional Prevalence Study of Impulse Control Disorders in Parkinson Disease. <i>Journal of Clinical Psychopharmacology</i> , 2013, 33, 691-694.	0.7	79
150	Mild affective symptoms in de novo Parkinson's disease patients: relationship with dopaminergic dysfunction. <i>European Journal of Neurology</i> , 2013, 20, 480-485.	1.7	52
151	Expanding the clinical phenotype of <i>DYT5</i> mutations: Is multiple system atrophy a possible one?. <i>Neurology</i> , 2013, 81, 301-302.	1.5	10
152	A Systematic Review of Catechol-O-Methyltransferase Inhibitors. <i>Clinical Neuropharmacology</i> , 2012, 35, 185-190.	0.2	43
153	Mild cognitive impairment and cognitive-motor relationships in newly diagnosed drug-naive patients with Parkinson's disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2012, 83, 601-606.	0.9	130
154	The Epidemiology and Clinical Manifestations of Dysexecutive Syndrome in Parkinson's Disease. <i>Frontiers in Neurology</i> , 2012, 3, 159.	1.1	31
155	Mild cognitive impairment in De Novo Parkinson's disease according to movement disorder guidelines. <i>Movement Disorders</i> , 2012, 27, 1706-1706.	2.2	9
156	Dopamine agonists and delusional jealousy in Parkinson's disease: A cross-sectional prevalence study. <i>Movement Disorders</i> , 2012, 27, 1679-1682.	2.2	48
157	The progression of non-motor symptoms in Parkinson's disease and their contribution to motor disability and quality of life. <i>Journal of Neurology</i> , 2012, 259, 2621-2631.	1.8	188
158	Metabolic changes induced by theta burst stimulation of the cerebellum in dyskinetic Parkinson's disease patients. <i>Parkinsonism and Related Disorders</i> , 2012, 18, 59-62.	1.1	51
159	The relationship between cerebral vascular disease and parkinsonism: The VADO study. <i>Parkinsonism and Related Disorders</i> , 2012, 18, 775-780.	1.1	58
160	A non-comparative assessment of tolerability and efficacy of duloxetine in the treatment of depressed patients with Parkinson's disease. <i>Expert Opinion on Pharmacotherapy</i> , 2012, 13, 2269-2280.	0.9	25
161	Depressive symptoms in Parkinson's disease. <i>Comprehensive Psychiatry</i> , 2012, 53, 727-731.	1.5	9
162	[123I]FP-CIT single photon emission computed tomography findings in drug-induced Parkinsonism. <i>Schizophrenia Research</i> , 2012, 139, 40-45.	1.1	32

#	ARTICLE	IF	CITATIONS
163	A molecular signature in blood identifies early Parkinson's disease. <i>Molecular Neurodegeneration</i> , 2012, 7, 26.	4.4	99
164	Frontal assessment battery scores and non-motor symptoms in parkinsonian disorders. <i>Neurological Sciences</i> , 2012, 33, 585-593.	0.9	18
165	Iowa gambling task in de novo Parkinson's disease: A comparison between good and poor performers. <i>Movement Disorders</i> , 2012, 27, 330-332.	2.2	6
166	Movement disorders: role of imaging in diagnosis. <i>Journal of Magnetic Resonance Imaging</i> , 2012, 35, 239-256.	1.9	39
167	Movement disorders: role of imaging in diagnosis. <i>Journal of Magnetic Resonance Imaging</i> , 2012, 35, spcone-spcone.	1.9	0
168	Dopamine Transporter SPECT Imaging in Corticobasal Syndrome. <i>PLoS ONE</i> , 2011, 6, e18301.	1.1	84
169	Impulsivity Is Associated With Decision-Making Deficits in De-Novo Parkinson's Disease. <i>Journal of Neuropsychiatry and Clinical Neurosciences</i> , 2011, 23, E26-E26.	0.9	0
170	Event-Based Prospective Memory in Newly Diagnosed, Drug-Naive Parkinson's Disease Patients. <i>Journal of the International Neuropsychological Society</i> , 2011, 17, 1158-1162.	1.2	12
171	Low frequency stimulation of the nucleus tegmenti pedunculopontini increases cortical metabolism in Parkinsonian patients. <i>European Journal of Neurology</i> , 2011, 18, 842-849.	1.7	32
172	The association between motor subtypes and alexithymia in de novo Parkinson's disease. <i>Journal of Neurology</i> , 2011, 258, 1042-1045.	1.8	30
173	Impulsivity and compulsivity in drug-naïve patients with Parkinson's disease. <i>Movement Disorders</i> , 2011, 26, 464-468.	2.2	139
174	Alexithymia Is Associated with Depression in de novo Parkinson's Disease. <i>Psychotherapy and Psychosomatics</i> , 2011, 80, 251-253.	4.0	28
175	Alexithymia may modulate decision making in patients with de novo Parkinson's disease. <i>Functional Neurology</i> , 2011, 26, 127-31.	1.3	9
176	The hOGG1 Ser326Cys polymorphism and Huntington's disease. <i>Toxicology</i> , 2010, 278, 199-203.	2.0	27
177	Non-motor symptoms in atypical and secondary parkinsonism: the PRIAMO study. <i>Journal of Neurology</i> , 2010, 257, 5-14.	1.8	140
178	Spectrum of addictions in Parkinson's disease: from dopamine dysregulation syndrome to impulse control disorders. <i>Journal of Neurology</i> , 2010, 257, 276-283.	1.8	38
179	Decision making in de novo Parkinson's disease. <i>Movement Disorders</i> , 2010, 25, 1432-1436.	2.2	56
180	Parkinson's Disease and pathological gambling: Results from a functional MRI study. <i>Movement Disorders</i> , 2010, 25, 2449-2453.	2.2	57

#	ARTICLE	IF	CITATIONS
181	Differences in nigrostriatal impairment in clinical variants of early Parkinson's disease: evidence from a FP-CIT SPECT study. <i>European Journal of Neurology</i> , 2010, 17, 626-630.	1.7	75
182	Deep Brain Stimulation of Pedunclopontine Tegmental Nucleus (PPTg) Promotes Cognitive and Metabolic Changes: A Target-Specific Effect or Response to a Low-Frequency Pattern of Stimulation?. <i>Clinical EEG and Neuroscience</i> , 2010, 41, 82-86.	0.9	39
183	Role of Pramipexole in the Management of Parkinson's Disease. <i>CNS Drugs</i> , 2010, 24, 829-841.	2.7	48
184	Nonmotor symptoms in Parkinson's disease: the dark side of the moon. <i>Future Neurology</i> , 2010, 5, 851-871.	0.9	10
185	Non-motor functions in parkinsonian patients implanted in the pedunclopontine nucleus: Focus on sleep and cognitive domains. <i>Journal of the Neurological Sciences</i> , 2010, 289, 44-48.	0.3	99
186	The hOGG1 Ser326Cys polymorphism is not associated with sporadic Parkinson's disease. <i>Neuroscience Letters</i> , 2010, 473, 248-251.	1.0	17
187	Levodopa response in dementia with lewy bodies: A 1-year follow-up study. <i>Parkinsonism and Related Disorders</i> , 2010, 16, 522-526.	1.1	45
188	Decreased and increased cortical activation coexist in de novo Parkinson's disease. <i>Experimental Neurology</i> , 2010, 224, 299-306.	2.0	30
189	The Role of Vascular Factors in Late-Onset Sporadic Alzheimers Disease. <i>Genetic and Molecular Aspects. Current Alzheimer Research</i> , 2009, 6, 224-237.	0.7	58
190	The PRIAMO study: A multicenter assessment of nonmotor symptoms and their impact on quality of life in Parkinson's disease. <i>Movement Disorders</i> , 2009, 24, 1641-1649.	2.2	1,171
191	Implantation of the nucleus tegmenti pedunclopontini in a PSP patient: Safe procedure, modest benefits. <i>Movement Disorders</i> , 2009, 24, 2020-2022.	2.2	22
192	Bilateral thalamic glioma presenting with parkinsonism. <i>Movement Disorders</i> , 2009, 24, 2168-2169.	2.2	11
193	Unilateral periodic limb movements: Is this a pointer for atypical presentation of corticobasal degeneration syndrome? A case report. <i>Movement Disorders</i> , 2009, 24, 2298-2299.	2.2	4
194	"Parkinson-dementia" diseases: A comparison by double tracer SPECT studies. <i>Parkinsonism and Related Disorders</i> , 2009, 15, 762-766.	1.1	25
195	P1.091 Parkinson's disease and pathological gambling: results from a fMRI study investigating cue induced brain activity. <i>Parkinsonism and Related Disorders</i> , 2009, 15, S52.	1.1	1
196	Impulse control disorders in Parkinson's disease: definition, epidemiology, risk factors, neurobiology and management. <i>Parkinsonism and Related Disorders</i> , 2009, 15, S111-S115.	1.1	101
197	Mitochondrial DNA single deletion in a patient with postural tremor. <i>Movement Disorders</i> , 2008, 23, 2098-2100.	2.2	4
198	Predictive value of nigrostriatal dysfunction in isolated tremor: A clinical and SPECT study. <i>Movement Disorders</i> , 2008, 23, 2049-2054.	2.2	35

#	ARTICLE	IF	CITATIONS
199	Mitochondrial DNA haplogroups do not influence the Huntington's disease phenotype. <i>Neuroscience Letters</i> , 2008, 444, 83-86.	1.0	11
200	How many parkinsonian patients are suitable candidates for deep brain stimulation of subthalamic nucleus? Results of a questionnaire. <i>Parkinsonism and Related Disorders</i> , 2008, 14, 266-267.	1.1	0
201	The mtDNA A8344G "MERRF" mutation is not a common cause of sporadic Parkinson disease in Italian population. <i>Parkinsonism and Related Disorders</i> , 2008, 14, 381-382.	1.1	13
202	CSF phosphorylated TAU protein levels correlate with cerebral glucose metabolism assessed with PET in Alzheimer's disease. <i>Brain Research Bulletin</i> , 2008, 76, 80-84.	1.4	49
203	The safety of dopamine agonists in the treatment of Parkinson's disease. <i>Expert Opinion on Drug Safety</i> , 2008, 7, 111-127.	1.0	9
204	How many parkinsonian patients are suitable candidates for deep brain stimulation of subthalamic nucleus? Results of a questionnaire. <i>Parkinsonism and Related Disorders</i> , 2007, 13, 528-531.	1.1	77
205	Visual hallucinations in Parkinson's disease are not influenced by polymorphisms of serotonin 5-HT2A receptor and transporter genes. <i>Neuroscience Letters</i> , 2007, 422, 228-231.	1.0	30
206	Influences of dopaminergic treatment on motor cortex in Parkinson disease: A MRI/MRS study. <i>Movement Disorders</i> , 2007, 22, 2170-2175.	2.2	32
207	Assessment of midbrain atrophy in patients with progressive supranuclear palsy with routine magnetic resonance imaging. <i>Acta Neurologica Scandinavica</i> , 2007, 116, 37-42.	1.0	82
208	Lack of association between mtDNA haplogroups and Alzheimer's disease in Tuscany. <i>Neurological Sciences</i> , 2007, 28, 142-147.	0.9	41
209	Long-term clinical evaluation in patients with Parkinson's disease and early autonomic involvement. <i>Parkinsonism and Related Disorders</i> , 2006, 12, 279-283.	1.1	8
210	No evidence for allelic association of serotonin 2A receptor and transporter gene polymorphisms with depression in Alzheimer disease. <i>Journal of Alzheimer's Disease</i> , 2006, 10, 371-378.	1.2	30
211	Brain perfusion effects of cholinesterase inhibitors in Parkinson's disease with dementia. <i>Journal of Neural Transmission</i> , 2006, 113, 1787-1790.	1.4	20
212	Association between amantadine and the onset of dementia in Parkinson's disease. <i>Movement Disorders</i> , 2006, 21, 1375-1379.	2.2	66
213	Biologic Features (Inflammation and Neoangiogenesis) and Atherosclerotic Risk Factors in Carotid Plaques and Calcified Aortic Valve Stenosis. <i>American Journal of Clinical Pathology</i> , 2006, 126, 494-502.	0.4	39
214	Assessing neuroprotection in Parkinson's disease: from the animal models to molecular neuroimaging in vivo. , 2006, , 133-141.		7
215	From mild cognitive impairment to dementia: a prevalence study in a district of Tuscany, Italy. <i>Acta Neurologica Scandinavica</i> , 2005, 112, 65-71.	1.0	72
216	Dopamine transporter imaging study in parkinsonism occurring in fragile X premutation carriers. <i>Neurology</i> , 2005, 65, 1971-1973.	1.5	36

#	ARTICLE	IF	CITATIONS
217	Psychiatric comorbidity in a population of Parkinson's disease patients. <i>European Journal of Neurology</i> , 2004, 11, 315-320.	1.7	173
218	Presynaptic nigro-striatal function in a group of Alzheimer's disease patients with parkinsonism: evidence from a dopamine transporter imaging study. <i>Journal of Neural Transmission</i> , 2004, 111, 1065-73.	1.4	45
219	Environmental factors and Parkinson's disease: a case-control study in the Tuscany region of Italy. <i>Parkinsonism and Related Disorders</i> , 2004, 10, 481-485.	1.1	25
220	Cerebral Perfusional Effects of Cholinesterase Inhibitors in Alzheimer Disease. <i>Clinical Neuropharmacology</i> , 2004, 27, 166-170.	0.2	50
221	Dopaminergic degeneration and perfusional impairment in Lewy body dementia and Alzheimer's disease. <i>Neurological Sciences</i> , 2003, 24, 162-163.	0.9	36
222	Cyclosporine-related posterior reversible encephalopathy syndrome (PRES) in non-transplant patient: a case report and literature review. <i>European Journal of Neurology</i> , 2003, 10, 461-462.	1.7	21
223	Decreased platelet cytochrome c oxidase activity is accompanied by increased blood lactate concentration during exercise in patients with Alzheimer disease. <i>Experimental Neurology</i> , 2003, 182, 421-426.	2.0	70
224	Serotonergic Polymorphisms (5-HTTLPR and 5-HT2A): Association Studies with Psychosis in Alzheimer Disease. <i>Genetic Testing and Molecular Biomarkers</i> , 2003, 7, 309-314.	1.7	47
225	Orthostatic Hypotension in De Novo Parkinson Disease. <i>Archives of Neurology</i> , 2003, 60, 1400.	4.9	93
226	Contribution of cerebellum and brainstem in the control of eye movement: evidence from a functional study in a clinical model. <i>Acta Neurologica Scandinavica</i> , 2002, 105, 32-39.	1.0	1
227	<sup>18</sup> F-dopa PET evidence that tolcapone acts as a central COMT inhibitor in Parkinson's disease. <i>Synapse</i> , 2002, 43, 201-207.	0.6	100
228	Comparison of endothelial function evaluated by strain gauge plethysmography and brachial artery ultrasound. <i>Atherosclerosis</i> , 2001, 158, 53-59.	0.4	38
229	Familial Progressive supranuclear Palsy. <i>Archives of Neurology</i> , 2001, 58, 1846.	4.9	42
230	SSRIs Do Not Worsen Parkinson's Disease: Evidence from an Open-Label, Prospective Study. <i>Clinical Neuropharmacology</i> , 2001, 24, 221-227.	0.2	97
231	Limbic encephalitis associated with thymic cancer: a case report. <i>Journal of Neurology</i> , 2001, 248, 1000-1002.	1.8	10
232	Mitochondrial DNA rearrangements in young onset parkinsonism: two case reports. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2001, 71, 685-687.	0.9	35
233	Delayed recovery of movement-related cortical function in Parkinson's disease after striatal dopaminergic grafts. <i>Annals of Neurology</i> , 2000, 48, 689-695.	2.8	246
234	Paraneoplastic choreic syndrome during non-Hodgkin's lymphoma. <i>Movement Disorders</i> , 2000, 15, 350-352.	2.2	49

#	ARTICLE	IF	CITATIONS
235	Paroxetine in Parkinson's disease: Effects on motor and depressive symptoms. <i>Neurology</i> , 2000, 55, 1216-1218.	1.5	124
236	Relationship Between Left Ventricular Mass and Endothelium-Dependent Vasodilation in Never-Treated Hypertensive Patients. <i>Circulation</i> , 1999, 99, 1991-1996.	1.6	90
237	The role of inheritance in sporadic Parkinson's disease: Evidence from a longitudinal study of dopaminergic function in twins. <i>Annals of Neurology</i> , 1999, 45, 577-582.	2.8	306
238	Acute and chronic effects of clozapine in essential tremor. <i>Movement Disorders</i> , 1999, 14, 468-472.	2.2	69
239	Angiotensin-Converting Enzyme Gene Polymorphism Is Associated With Endothelium-Dependent Vasodilation in Never Treated Hypertensive Patients. <i>Hypertension</i> , 1998, 31, 900-905.	1.3	66
240	Clozapine in Parkinson's disease tremor. <i>Neurology</i> , 1997, 49, 1587-1590.	1.5	94
241	A case of pelvic floor myoclonic jerk syndrome. <i>Movement Disorders</i> , 1996, 11, 331-333.	2.2	4
242	Myopathic involvement in two cases of Hallervorden-Spatz disease. <i>Brain and Development</i> , 1995, 17, 286-290.	0.6	9
243	Clozapine in Huntington's chorea. <i>Neurology</i> , 1994, 44, 821-821.	1.5	58